Reviva Pharmaceuticals Holdings, Inc. Convertible Notes Payable, Noncurrent
Reviva Pharmaceuticals Holdings, Inc. (RVPH) had Convertible Notes Payable, Noncurrent of $3.77 million as of 2019-12-31, per its 10-K/A filed 2021-05-07.
Discontinued › Balance Sheet › Liabilities
us-gaap:ConvertibleLongTermNotesPayable · last filed 2021-05-07
- 2019-12-31: Convertible Notes Payable, Noncurrent $3.77M.
| Period end | Convertible Notes Payable, Noncurrent |
|---|---|
| 2019-12-31 | $3.77M 10-K/A · filed 2021-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |